CORDY

News

  1. Top
  2. Business area
  3. News

Development of Cystatin SN as a new diagnostic marker for colon cancer Reported at The 93rd Annual Meeting of the Japanese Society of Gastroenterology

2007/04/21

Perseus Proteomics Inc. announced about a new diagnostic marker specific for colon cancer, Cystatin SN, on a symposium at The 93rd Annual Meeting of the Japanese Society of Gastroenterology held on April, 21st 2007, collaborated with professor Atsushi Nakajima and Dr. Kyoko Yomemitsu in Department of Molecular Enterology, Yokohama City University Graduate School of Medicine. Cystatin SN is a secretary protein with a molecular weight of 16kD, which highly expressed in colon cancer found by GeneChip Analysis at Research Center for Advanced Science and Technology (RCAST). Perseus Proteomics has been developing a diagnostic kit for this molecule as a participant of a project, "Developing Integral Diagnosis and Therapy for Cancer and Metabolic Disease with Genome Based Antibody Therapeutic Drug funded by National Institute of Biomedical Innovation (project leader: professor Tatsuhiko Kodama at RCAST). Cystatin SN is a part of this project collaborated with Yokohama City University Graduate School of Medicine. Regarding to data obtained with the reagent established by Perseus Proteomics, serum concentration of Cystatin SN is correlated with pathophysiologic status, where especially progressive colon cancer patients is distinguished from healthy people by statistical analysis. It suggests this marker is superior to other current markers, such as CEA or CA19-9, to identify presence of cancer. There is no correlation with age or sex. Together all, it may anticipate Cystatin SN will recognize as a new colon cancer marker. We will proceed further study under larger population and characterize the mechanisms for Cystitis SN expression. Pressrelease